Weight Loss Outcomes Associated With Semaglutide Treatment for Patients With Overweight or Obesity

Abstract

The results of this cohort study suggest that weekly 1.7-mg and 2.4-mg doses of semaglutide were associated with weight loss similar to that seen in randomized clinical trials. Studies with longer periods of follow-up are needed to evaluate prolonged weight loss outcomes.